All News

Analyzing outcomes from the COVID-19, influenza, and pneumococcal vaccines, researchers explored the effectiveness and patient hesitancy surrounding each vaccine.

A series of posters presented at AMCP Nexus 2024 highlighted the evolving landscape of women's health, focusing on the use of medications for preterm birth prevention and the adoption of telehealth for prenatal consultations.

A recent study found the percentage of type 1 diabetes patients who were prescribed either GLP-1s or SGLT2 inhibitors increased from 0.7% to 8.3% between 2010 and 2023.

The new recommendations suggest vaccination at age 50, rather than age 65.

Adding to the mail-order options within big chain pharmacy, Walmart is promising prescription delivery in as quickly as 30 minutes.

Research presented at AMCP Nexus 2024 underscored and explored the need for treatments that can prevent or mitigate flare-ups in patients with AD.

Nina Vadiei, PharmD, BCPP, a clinical associate professor at UT Austin and a clinical pharmacy specialist in psychiatry at San Antonio State Hospital, discusses her career as a psychiatric pharmacist.

New research presented at AMCP Nexus 2024 highlighted the effectiveness and cost-effectiveness of various migraine treatments, including onabotulinumtoxinA and fremanezumab, as well as the importance of migraine education programs for improving patient outcomes.

Researchers addressed the association between sleep patterns and digestive diseases, as well as patients’ genetic likeliness of developing future digestive complications.

In a comprehensive literature review, researchers addressed the impact cardiac surgery has on gastrointestinal outcomes.

Mark Garofoli, PharmD, MBA, BCGP, CPE, CTTS, discusses what sessions he is looking forward to and key themes he expects to be the topic of conversation at NCPA 2024.

Abrysvo is the only RSV vaccine approved for use in this age group.

Investigators conducted a study to assess the impact of combined diet and exercise interventions in patients with type 2 diabetes.

Posters presented at IDWeek 2024 provided new insights into the impact of COVID-19 infection and vaccination on women’s health.

Results of the SOUL clinical trial will be presented at a scientific meeting in 2025.

Analyzing copayments and coverage plans for popular weight-loss drugs in the US, researchers addressed the cost-effectiveness of GLP-1 medications for treating obesity.

A discussion with Madison Irwin, PharmD, BCPS, clinical pharmacist specialist in palliative care at University of Michigan Health and clinical assistant professor at the University of Michigan College of Pharmacy.

Three posters showcased at IDWeek 2024 focused on enhancing access to HIV prevention and treatment, as well as increasing uptake of pre-exposure prophylaxis (PrEP) among women.

Opioid use disorder risk was higher in a cohort of patients with chronic pain without disability.

Researchers explored the stigmatization of sexually transmitted infections across film while also identifying inaccuracies in STI-related content on Tik Tok.

Multimodal analgesia provides more effective pain management—and leads to a decrease in opioid use.

Researchers explored the overall efficacy of various pediatric vaccines and their effects on antibiotic use, while also addressing vaccine hesitancy among parents.

Pharmacist education can positively impact patient counseling around vaccinations in older adults.

Suzetrigine could represent the first new nonopioid drug in a distinct class of pain medications in approximately 20 years.

Normalizing conversations around mental health in older adult populations can improve outcomes.

A conversation with Rakesh Jain, MD, MPH, clinical professor in the Department of Psychiatry at Texas Tech University School of Medicine.

In case you missed it, this week we had stories about medication adherence and breast cancer outcomes, new vaccines in the pipeline, independent pharmacies saying no to Medicare drug price, and more.